(Q37725994)

22 August 2017

1 reference

title

Novel inhibitors in development for hepatocellular carcinoma (English)

1 reference

22 August 2017

author name string

Marcus Alexander Wörns

series ordinal

1

1 reference

22 August 2017

Peter Robert Galle

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

615-629

1 reference

Global cancer statistics, 2002

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Obesity and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Systemic therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Hepatocellular carcinoma pathogenesis: from genes to environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

New therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Targeted therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Sunitinib and the benefits of a negative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Growth factors in liver development, regeneration and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

mTOR inhibitors for hepatocellular cancer: a forward-moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Senescence and immortality in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Activation of the hedgehog pathway in human hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767418

10.1517/13543781003767418

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference